Global Health Ventures Inc., or the "Company" a Specialty Pharma is pleased to announce today that it has completed the prototype manufacturing of the drug "X-Excite" Global's male enhancement drug. The manufacturing of the product was carried out under contract with Vida Pharma of Montreal, Canada. Vida Pharma specialized in the designing of the new tablet size, taste, and hardness. [More]

Prostate cancer is the second most common cancer in American men. One in six men will be diagnosed during his lifetime, according to the American Cancer Society. [More]

Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy. [More]

On Thursday, November 5th, AIDS Healthcare Foundation (AHF), the largest global AIDS organization, which provides medical care and/or services to more than 120,000 individuals in 22 countries worldwide, opened a Men's Wellness Center at the new ‘AHF Blair Underwood Healthcare Center’ located in Washington D.C. [More]

The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection. [More]

Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective inhibitor of phosphodiesterase versus placebo. [More]

Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. [More]

Fox Chase Cancer Center researchers report that radiation therapy alone can reduce prostate specific antigen (PSA) levels below detectable amounts in prostate cancer patients. Patients who have an undetectable level of PSA after therapy have less chance of biochemical failure than other patients and a good chance of being cured. [More]

The American Urological Association (AUA) is aware of recent news reports disparaging prostate cancer testing. We are concerned that these reports are causing significant confusion for patients and we wish to clarify our recommendations on prostate cancer testing with the prostate-specific antigen (PSA) test and digital rectal exam (DRE). The AUA strongly supports early prostate cancer detection and feels it is in a man's best interest to consider being tested for prostate cancer. [More]

A shorter, five-week course of radiation treatment that delivers higher doses of radiation in fewer sessions, known as hypofractionation, appears to be just as effective and as safe in reducing the risk of prostate cancer from returning as standard radiation therapy, yet is delivered in two-and-a-half weeks less time, according to interim results of a randomized study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO). [More]

Men with lower cholesterol are less likely than those with higher levels to develop high-grade prostate cancer - an aggressive form of the disease with a poorer prognosis, according to results of a Johns Hopkins collaborative study. [More]

A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed? [More]

Proton beam therapy can be safely delivered to men with prostate cancer and has minimal urinary and rectal side effects, according to a study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago. [More]

Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago. [More]

Penn Medicine will lead a new national $45 million clinical trial to test whether testosterone therapy can favorably affect certain conditions affecting older men. Low serum testosterone may contribute to a number of problems affecting older men, including decreased ability to walk, loss of muscle mass and strength, decreased vitality, decreased sexual function, impaired cognition, cardiovascular disease and anemia. While testosterone normally decreases with age, in some men, low levels of testosterone may contribute to these debilitating conditions. [More]